HULUWA(SH:605199) Xin Lang Cai Jing·2025-12-30 06:14Core Viewpoint - Hainan Huluwa Pharmaceutical Group Co., Ltd. and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to potential claims from affected investors [1][2][4] Group 1: Investigation Details - The CSRC issued a notice of investigation on December 26, 2025, regarding the company and its chairman for alleged information disclosure violations [1][3] - The Hainan Securities Regulatory Bureau identified issues in the company's sales practices in March 2025, including premature revenue recognition and abnormal sales prices, resulting in inaccurate financial data in periodic reports [4] - The company failed to timely disclose a profit warning for the negative net profit in 2024, only releasing the information in April 2025, which led to criticism from the Shanghai Stock Exchange [4] Group 2: Investor Compensation - Affected investors who purchased shares between August 29, 2024, and April 22, 2025, and still hold them, can voluntarily register for compensation through the "Sina Investor Rights Protection Platform" [2][3] - The law firm involved has a history of successfully handling securities disputes and has represented investors in multiple compensation cases against various listed companies [3][4]